<DOC>
	<DOCNO>NCT02721004</DOCNO>
	<brief_summary>This open-label , non-interventional study evaluate efficacy safety rheumatoid arthritis participant receive tocilizumab per product label .</brief_summary>
	<brief_title>Efficacy Safety Study RoActemra ( Tocilizumab ) Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Participants rheumatoid arthritis receive tocilizumab per product label No specific exclusion criterion specify noninterventional trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>RoActemra</keyword>
	<keyword>Tocilizumab</keyword>
</DOC>